Clinical OMICS

MAY-JUN 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1117801

Contents of this Issue

Navigation

Page 32 of 50

www.clinicalomics.com May/June 2019 Clinical OMICs 31 breast cancer cell line, which is ethnically classified as black, actually carried mostly Native American ancestry. The most egregious misclassification, however, was the E006AA-hT cell line, and the ATCC has since placed E006AA-HT "on hold" as of March 6 and the cell line "is not available for distribution," said an ATCC spokesperson. The misclassification has reached the level of the National Institutes of Health (NIH), with the NIH Office of Extramu- ral Research saying that they are "aware that the cell line E006AA-hT, originally classified as African-American, was recently found to be of European descent." Within the prostate cancer research community, the reac- tion to this news has been mixed. "There are people that are excited about it, but then there are people who are kind of nervous or upset because they've used the cell line," said Kittles. For instance, researchers may have cited the cell line in grant proposals. In addition, the E006AA-hT cell line has been used in studies that appear in peer-reviewed journals, such as Scientific Reports (a Nature Research journal), Carcino- genesis, and Cancer Research. "Now, it's almost like they have to go back and fix all of that," said Kittles. The iceberg beneath The ancestral misclassifi- cation of the E006AA-hT is just the tip of the iceberg. The study authors asserted that the E006AA-hT cell line may not even be pros- tate cancer, but instead re n a l c e l l c a rc i n o m a because according to the ATCC website, a disclaimer warns that the short tan- dem repeat profile of the E006AA-hT cell line has an 86 percent match with the 786-O cell line, which is derived from renal cell carcinoma. Furthermore, Kittles personally genotyped the parental cell line E006AA, which has been around for a decade lon- ger than the E006AA-hT cell line, and several times found it to be of European ancestry. The parental cell line was first described as being obtained from an African-Amer- ican patient with prostate cancer in a 2004 journal article (continued on next page) James Rae, Ph.D., associate professor, University of Michigan Photo credit: The Hope Foundation for Cancer Research Rick Kittles, Ph.D., associate director, Comprehensive Cancer Center, City of Hope KATERYNA KON / Science Photo Library / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2019